Buffett’s Berkshire pares drug holdings, sheds Axalta, Biogen
Warren Buffett’s Berkshire Hathaway Inc (BRKa.N) said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co (MRK.N) spinoff, Organon & Co (OGN.N).
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.
